Achieve Life Sciences Proposes Public Offering for Growth
Achieve Life Sciences Proposes a New Public Offering
SEATTLE and VANCOUVER, British Columbia — Achieve Life Sciences, Inc. (NASDAQ: ACHV) has recently made an announcement regarding a proposed underwritten public offering. This offering aims to sell shares of its common stock, along with pre-funded warrants that allow the purchase of common stock, and accompanying common warrants. The company is also planning to provide underwriters with a 30-day option to purchase an additional 15% of the offered shares and warrants. All securities will be issued directly by Achieve, and the completion of this offering is contingent on market conditions.
Lead Managers for the Offering
Citizens Capital Markets and Raymond James have stepped in as joint book-running managers for this proposed offering. Additionally, Lake Street Capital Markets, LLC will provide financial advisory services to Achieve throughout this endeavor. The utilization of proceeds from this offering is aimed at accelerating the advancement of cytisinicline, which is currently under review for FDA marketing approval.
Intended Use of Offering Proceeds
The funds raised from this offering will be directed towards the continued development of cytisinicline, a promising treatment for nicotine dependence aimed at smoking cessation, and will also support working capital and general corporate requirements. Achieve Life Sciences is committed to combatting the epidemic of nicotine dependence through its innovative solutions, seeking to make a significant impact on public health.
Regulatory Considerations and Future Plans
The company plans to offer these securities under a registration statement on Form S-3 that has already been filed and accepted by the SEC. Investors will soon be able to review a preliminary prospectus regarding the offering, and when available, it will include all requisite details. The final terms of this public offering will also be made available in a subsequent prospectus supplement.
Understanding the Burden of Nicotine Addiction
Globally, smoking remains a leading cause of preventable deaths, with millions of adults affected by nicotine addiction. In the United States alone, over 29 million adults smoke combustible cigarettes. Furthermore, another 17 million use e-cigarettes, highlighting the urgent need for effective cessation aids. Cytisinicline is designed to address this need, especially as there currently lack FDA-approved treatments aimed specifically at individuals looking to quit e-cigarettes.
About Cytisinicline
Cytisinicline, a natural alkaloid, has shown significant promise in treating nicotine addiction by engaging with nicotinic receptors in the brain, thereby reducing cravings and the satisfaction derived from nicotine consumption. These attributes make cytisinicline a vital part of Achieve’s strategy in offering new solutions for smoking cessation and broader nicotine dependency issues.
Commitment to Developing Innovative Solutions
Achieve Life Sciences has demonstrated a strong commitment to addressing nicotine dependence through advanced research and clinical trials. In June 2025, they submitted a New Drug Application for cytisinicline to the FDA, fortified by the success of completed Phase 3 studies and an open-label safety study. This approval would pave the way for broader access to this groundbreaking treatment.
Frequently Asked Questions
What is the purpose of Achieve Life Sciences' public offering?
The public offering aims to raise funds for the further development of cytisinicline, addressing nicotine addiction and supporting general corporate expenses.
Who is managing the public offering?
The offering is managed by Citizens Capital Markets and Raymond James, with Lake Street Capital Markets acting as a financial advisor.
What is cytisinicline?
Cytisinicline is a plant-derived alkaloid designed to aid nicotine addiction treatment by reducing cravings and the satisfaction gained from nicotine products.
How will the proceeds from the offering be used?
The proceeds will fund the advancement of cytisinicline through its FDA approval process and provide working capital for the company's initiatives.
How many adults smoke in the U.S.?
Approximately 29 million adults in the U.S. smoke combustible cigarettes, contributing to significant health issues related to smoking.
About The Author
Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
